PMID- 26114844
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20150627
IS  - 2325-8179 (Electronic)
IS  - 2325-8160 (Linking)
VI  - 46
IP  - 6
DP  - 2015 Jun
TI  - Quantification of Change in Pigment Epithelial Detachment Volume and Morphology 
      After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant 
      Neovascular AMD: 18-Month Results.
PG  - 638-41
LID - 10.3928/23258160-20150610-07 [doi]
AB  - BACKGROUND AND OBJECTIVE: To quantitatively evaluate the change in pigment 
      epithelial detachment (PED) morphology on spectral-domain optical coherence 
      tomography (SD-OCT) 18 months after the transition to intravitreal aflibercept in 
      patients with neovascular age-related macular degeneration (AMD) with PED 
      recalcitrant to monthly intravitreal bevacizumab or ranibizumab. PATIENTS AND 
      METHODS: Retrospective case series examining patients with neovascular AMD who 
      had a persistent fibrovascular or serous PED on SD-OCT. PED volume was calculated 
      by manually outlining the PED on individual OCT slices of the raster scan and 
      multiplying by the pixel dimensions. RESULTS: Eleven eyes of 10 patients who had 
      received an average of 25.7 +/- 20.1 (range: 6 to 70) prior bevacizumab or 
      ranibizumab injections over a period of 26.6 +/- 19.8 months (range: 4 to 63) were 
      included. PED volume decreased with aflibercept from 0.687 +/- 0.837 mm(3) to 0.562 
      +/- 0.705 mm(3) (P = .02), a decrease of 19% +/- 12.27%. CONCLUSION: After 18 months 
      of aflibercept, recalcitrant PED volumes were reduced by 19% while preserving 
      visual acuity in eyes with neovascular AMD.
CI  - Copyright 2015, SLACK Incorporated.
FAU - Kanesa-Thasan, Aditya
AU  - Kanesa-Thasan A
FAU - Grewal, Dilraj S
AU  - Grewal DS
FAU - Gill, Manjot K
AU  - Gill MK
FAU - Lyon, Alice T
AU  - Lyon AT
FAU - Mirza, Rukhsana G
AU  - Mirza RG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ophthalmic Surg Lasers Imaging Retina
JT  - Ophthalmic surgery, lasers & imaging retina
JID - 101599215
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Bevacizumab/therapeutic use
MH  - Drug Resistance
MH  - Drug Substitution
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/*drug therapy/physiopathology
MH  - Male
MH  - Ranibizumab/therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/*therapeutic use
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retinal Detachment/*diagnosis
MH  - Retinal Neovascularization/*drug therapy/physiopathology
MH  - Retinal Pigment Epithelium/*pathology
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2015/06/27 06:00
MHDA- 2016/02/24 06:00
CRDT- 2015/06/27 06:00
PHST- 2014/11/23 00:00 [received]
PHST- 2015/05/05 00:00 [accepted]
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - 10.3928/23258160-20150610-07 [doi]
PST - ppublish
SO  - Ophthalmic Surg Lasers Imaging Retina. 2015 Jun;46(6):638-41. doi: 
      10.3928/23258160-20150610-07.